Clinical Trials Logo

Filter by:
NCT ID: NCT03750058 Completed - Clinical trials for Cardiac Resynchronisation Therapy

Acute Assessment of a Micro Multipolar Lead for Enhanced Cardiac Resynchronisation Therapy

AXONE-Acute
Start date: August 8, 2018
Phase: N/A
Study type: Interventional

Pilot study to evaluate the performance of a lead below 2 French with specific distal shape to deliver efficient LV pacing

NCT ID: NCT03749642 Completed - Clinical trials for Painful Diabetic Neuropathy

Trazodone/Gabapentin Fixed Dose Combination Products in Painful Diabetic Neuropathy

Start date: November 22, 2018
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to collect preliminary information on the effect of three doses of trazodone/gabapentin FDC products on pain intensity in patients with painful diabetic neuropathy after 8-week treatment period.

NCT ID: NCT03749304 Completed - Clinical trials for Surgical Procedure, Unspecified

Monitoring Analgesia by ANI (Analgesia The Nociception Index)

ANI-MICI
Start date: March 16, 2014
Phase: N/A
Study type: Interventional

The objective of this research is to study the variations of the ANI(Analgesia The Nociception Index) according to 2 periods: the "NoStim" period before surgical incision under general anesthesia and the period of hemodynamic reactivity "ReactHemo" peroperative. This period is defined by a 20% increase in FC and / or PAS (the only gold standard today).

NCT ID: NCT03748823 Completed - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Start date: February 19, 2019
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate pharmacokinetics (PK) of ravulizumab administered subcutaneously via an on-body delivery system (OBDS) compared with intravenously administered ravulizumab in adult participants with PNH who are clinically stable on eculizumab for at least 3 months prior to study entry.

NCT ID: NCT03748225 Completed - Bereaved Families Clinical Trials

Incidence and Risk Factors of Prolonged Grief in Palliative Care Units

FAMI-LIFE
Start date: February 4, 2019
Phase:
Study type: Observational

The purpose of this study is to assess the incidence and risk factors of prolonged grief in family members of patients died in French palliative care units and to explore experience of bereaved families to build a scientifically valid management prevention program.

NCT ID: NCT03748134 Completed - Clinical trials for Esophageal Squamous Cell Carcinoma

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )

Start date: December 24, 2018
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind multi-center, phase III study comparing the efficacy and safety of sintilimab or placebo in combination with chemotherapy as first-line treatment in subjects with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma. After the interim analysis conducted by the iDMC, an open-label assignment of experimental arm therapy will continue in regions outside of China, in order to further evaluate the efficacy and safety of sintilimab in combination with chemotherapy in subjects representing the western population with advanced esophageal squamous cell carcinoma

NCT ID: NCT03747939 Completed - Clinical trials for Arthritis, Psoriatic

Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.

FOREMOST
Start date: December 31, 2018
Phase: Phase 4
Study type: Interventional

This clinical study will test the effects of a drug called apremilast in oligoarticular psoriatic arthritis with less than 5 years of disease duration. In previous studies, apremilast has been shown to be safe and efficacious in reducing signs and symptoms of psoriatic arthritis, as well as improving physical function. This study will compare the effects of apremilast to placebo on psoriatic arthritis subjects in which the number of affected joints is limited (greater than 1 but less or equal to 4). About 285 patients worldwide will take part in this study.

NCT ID: NCT03747874 Completed - Clinical trials for Obstructive Sleep Apnea

OSA and Sudden Sensorineural Hearing Loss

SAS-SB
Start date: November 19, 2018
Phase: N/A
Study type: Interventional

This study studies the prevalence between obstructive sleep apnea syndrome and sensorineural hearing loss. We recruit patients who have been treated for sudden sensorineural hearing loss in Poitiers' University Hospital between 2010 et 2017, and we detect if they have OSA with a ventilatory polygraphy.

NCT ID: NCT03747315 Completed - Clinical trials for Familial Mediterranean Fever

A Diagnostic Test for Familial Mediterranean Fever

DEPIST-FMF
Start date: December 15, 2018
Phase:
Study type: Observational

Familial Mediterranean Fever (FMF) is the most common auto-inflammatory disease (prevalence: 1-5 / 10,000 inhabitants). It is due to mutations of the MEFV gene, encoding variants of the Pyrin inflammasome. Inflammasomes are protein complexes of innate immunity producing pro-inflammatory cytokines (interleukin-1β). In vitro, preliminary results demonstrated that activation of the Pyrin inflammasome (measured by interleukin-1β concentration) by kinase inhibitors is significantly increased in FMF patients compared to subjects with a similar clinical picture, and healthy controls. In addition, a measure of cell death yielded significant results in differentiating patients from controls. The investigators hypothesize that this fast and simple functional test can serve as a diagnostic tool for FMF.

NCT ID: NCT03746860 Completed - Clinical trials for Allergic Rhinitis Due to House Dust Mite

N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in France

CARIOCA
Start date: May 9, 2018
Phase:
Study type: Observational

Non-interventional study to investigate the safety and tolerability of allergy immunotherapy ACARIZAX® 12 SQ-HDM in real-life clinical practice in adults patients (>18 years) with house dust mite allergy over a period of 12 months.